从事分子肿瘤药理学及分子靶向抗肿瘤新药研发。

1.小分子激酶抑制剂抗肿瘤新药研发

2.双/多靶点抗肿瘤新药研发

3.抗肿瘤恶病质新药研发

4. 肿瘤多药耐药逆转剂新药研发

中国药理学会肿瘤药理与化疗专业委员会委员。

  1985年毕业于福建医科大学医疗系获学士学位，1991年毕业于福建医科大学获肿瘤药理学专业硕士学位，1999年毕业于中科院上海药物研究所获分子肿瘤药理学专业博士学位。1999-2002年在美国田纳西大学和St. Jude儿童研究医院从事博士后研究工作。2002年加入中科院上海药物研究所国家新药重点研究室肿瘤药理组研究员。2006年加入亚盛医药研发有限公司任生物部总监。2007年加入罗氏研发中心（中国），先后任物筛选技术部主任、分子肿瘤部主任、体内药理学部主任等职。2013年加入华东师范大学。国家药品监督管理局（SFDA）药品审评中心审评专家、中国药理学会肿瘤药理与化疗专业委员会委员。在高质量杂志上发表研究文章80篇（SCI收录71篇），申请专利24项（14项授权）。先后主持多项国家科技部863和973课题及国家自然科学基金项目。参与发明一个1.1类新药进入临床，领导完成数个抗肿瘤新药临床前研发的完整过程，并领导参与新药临床I/IIa期实验。

代表性论文（Selected Research Publications）： 

1.Dual VEGFR2 and Aurora kinase inhibitor R1498 as a novel treatment for gastric cancer and hepatocellular cancer.PLOS ONE2013; 8(6): e65264.

2.Targeting cadherin-17 inactivates Ras/Raf/MEK/ERK signaling and inhibits cell proliferation in gastric cancer.PLOS ONE2014; 9(1): e85296.

3.Targeting NEK2 as a promising therapeutic approach for cancer treatment.Cell Cycle2016; 15(7):895-907.

4.Design, Synthesis, and Biological Evaluation of New Cathepsin B-Sensitive Camptothecin Nanoparticles Equipped with a Novel Multifuctional Linker.Bioconjugate Chemistry2016; 27(5):1267-75.

5.NIR fluorescent DCPO glucose analogues and their application in cancer cell imaging.RSC Adv2016; 6(85): 81894-901.

6.Preclinical activity of MBM-5 in gastrointestinal cancer by inhibiting NEK2 kinase activity.Oncotarget2016; 7(48):79327-41.

7.Antitumor activity of TY-011 against gastric cancer by inhibiting Aurora A, Aurora B and VEGFR2 kinases.J Exp Clin Cancer Res2016; 35(1):183-97.

8.Characterization of a near-infrared fluorescent dcpo-tagged glucose analogue for cancer cell imaging. J Photoch Photobio B 2017;166:264-71.

9.Structure-based design and synthesis of imidazo[1,2-a]pyridine derivatives as noveland potent Nek2 inhibitors with in vitro and in vivo antitumor activities.Eur J Med Chem.2017;126:1083-106.

10.ES2 enhances the efficacy of chemotherapeutic agents in ABCB1-overexpressing cancer cells in vitro and in vivo.Pharmacol Res 2018 Mar; 129:388-399.

11.Tumor-targeting efficacy of aBF211 prodrug through hydrolysis by fibroblast activation protein-α.Acta Pharmacol Sin2018 Mar; 39(3):415-424.

12.Pyrrolidine Dithiocarbamate (PDTC) Attenuates Cancer Cachexia by Affecting Muscle Atrophy and Fat Lipolysis.Front Pharmacol2017 Dec 12; 8:915.

13.Design and synthesis of aryloxypropanolamine as β3-adrenergic receptor antagonist in cancer and lipolysis.Eur J Med Chem.2018 Apr 25;150:757-770.

14.Synthesis and evaluation of novel dimethylpyridazine derivatives as hedgehog signaling pathway inhibitors.Bioorg Med Chem.2018 23; 26:3308-3320. 

15. L-4, a Well-Tolerated and Orally Active Inhibitor of Hedgehog Pathway, Exhibited Potent Anti-tumor Effects Against Medulloblastoma in vitro and in vivo.Front Pharmacol2019 Feb 21;10:89. 

16. SiBaoChongCao exhibited anti-fatigue activities and ameliorated cancer cachexia in mice. RSC Adv.2019 Jun; 9: 17440-56.